New drug candidates for depression – a nationwide population‐based study
Objective To investigate whether continued use of non‐aspirin NSAID, low‐dose aspirin, high‐dose aspirin, statins, allopurinol and angiotensin agents decreases the rate of incident depression using Danish nationwide population‐based registers. Methods All persons in Denmark who purchased the exposur...
Gespeichert in:
| Veröffentlicht in: | Acta psychiatrica Scandinavica 2019-01, Vol.139 (1), p.68-77 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 1 |
| container_start_page | 68 |
| container_title | Acta psychiatrica Scandinavica |
| container_volume | 139 |
| creator | Kessing, L.V. Rytgaard, H. C. Gerds, T. A. Berk, M. Ekstrøm, C. T. Andersen, P. K. |
| description | Objective
To investigate whether continued use of non‐aspirin NSAID, low‐dose aspirin, high‐dose aspirin, statins, allopurinol and angiotensin agents decreases the rate of incident depression using Danish nationwide population‐based registers.
Methods
All persons in Denmark who purchased the exposure medications of interest between 1995 and 2015 and a random sample of 30% of the Danish population was included in the study. Two different outcome measures were included, (i) a diagnosis of depressive disorder at a psychiatric hospital as in‐patient or out‐patient and (ii) a combined measure of a diagnosis of depression or use of antidepressants.
Results
A total of 1 576 253 subjects were exposed to one of the six drugs of interest during the exposure period from 2005 to 2015. Continued use of low‐dose aspirin, statins, allopurinol and angiotensin agents was associated with a decreased rate of incident depression according to both outcome measures. Continued uses of non‐aspirin NSAIDs as well as high‐dose aspirin were associated with an increased rate of incident depression.
Conclusion
The findings support the potential of agents acting on inflammation and the stress response system in depression as well as the potential of population‐based registers to systematically identify drugs with repurposing potential. |
| doi_str_mv | 10.1111/acps.12957 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2099886211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2099886211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4197-ad6ffe0438bed6c1b7e3db01f476618af332f42014ff6dc6277d90e1a333cfff3</originalsourceid><addsrcrecordid>eNp9kM1KxDAURoMoOv5sfAAJuBGhem_TSdqlDP7BoIIK7kLa3Eil09ZkyjC7eQTBN_RJ7DjqwoXZXD44HMJhbB_hBPt3aoo2nGCcDdUaG6AEiCBJ1DobAABGMoOnLbYdwks_hwjpJtsSgGkspBiw8Q3NuPXdMy9MbUtrphS4azy31HoKoWxq_rF454bXZtqPWWmJt03bVV_zY_GWm0CWh2ln57tsw5kq0N733WGPF-cPo6tofHt5PTobR0WCmYqMlc4RJCLNycoCc0XC5oAuUVJiapwQsUtiwMQ5aQsZK2UzIDRCiMI5J3bY0crb-ua1ozDVkzIUVFWmpqYLOoYsS1MZI_bo4R_0pel83f9OxzhUGSSoltTxiip8E4Inp1tfToyfawS9bKyXjfVX4x4--FZ2-YTsL_oTtQdwBczKiub_qPTZ6O5-Jf0E0ayIbQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157904171</pqid></control><display><type>article</type><title>New drug candidates for depression – a nationwide population‐based study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kessing, L.V. ; Rytgaard, H. C. ; Gerds, T. A. ; Berk, M. ; Ekstrøm, C. T. ; Andersen, P. K.</creator><creatorcontrib>Kessing, L.V. ; Rytgaard, H. C. ; Gerds, T. A. ; Berk, M. ; Ekstrøm, C. T. ; Andersen, P. K.</creatorcontrib><description>Objective
To investigate whether continued use of non‐aspirin NSAID, low‐dose aspirin, high‐dose aspirin, statins, allopurinol and angiotensin agents decreases the rate of incident depression using Danish nationwide population‐based registers.
Methods
All persons in Denmark who purchased the exposure medications of interest between 1995 and 2015 and a random sample of 30% of the Danish population was included in the study. Two different outcome measures were included, (i) a diagnosis of depressive disorder at a psychiatric hospital as in‐patient or out‐patient and (ii) a combined measure of a diagnosis of depression or use of antidepressants.
Results
A total of 1 576 253 subjects were exposed to one of the six drugs of interest during the exposure period from 2005 to 2015. Continued use of low‐dose aspirin, statins, allopurinol and angiotensin agents was associated with a decreased rate of incident depression according to both outcome measures. Continued uses of non‐aspirin NSAIDs as well as high‐dose aspirin were associated with an increased rate of incident depression.
Conclusion
The findings support the potential of agents acting on inflammation and the stress response system in depression as well as the potential of population‐based registers to systematically identify drugs with repurposing potential.</description><identifier>ISSN: 0001-690X</identifier><identifier>EISSN: 1600-0447</identifier><identifier>DOI: 10.1111/acps.12957</identifier><identifier>PMID: 30182363</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Allopurinol ; Allopurinol - adverse effects ; Allopurinol - therapeutic use ; Angiotensin ; Angiotensins - adverse effects ; Angiotensins - therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal - adverse effects ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Antidepressants ; Antidepressive Agents - therapeutic use ; Aspirin ; Aspirin - adverse effects ; Aspirin - therapeutic use ; Denmark - epidemiology ; Depression - diagnosis ; Depression - drug therapy ; Depression - epidemiology ; depressive disorder ; Depressive Disorder - diagnosis ; Depressive Disorder - drug therapy ; Depressive Disorder - epidemiology ; Diagnosis ; Drug development ; Drug dosages ; Drug Repositioning - methods ; Drug Repositioning - statistics & numerical data ; drug repurposing ; Female ; Gout Suppressants - adverse effects ; Gout Suppressants - therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Incidence ; inflammation ; Inflammation - drug therapy ; Male ; Mental depression ; Middle Aged ; Nonsteroidal anti-inflammatory drugs ; NSAID ; Outcome Assessment, Health Care ; Population ; Population studies ; Population-based studies ; Registries ; Statins ; stress ; Stress, Physiological - drug effects</subject><ispartof>Acta psychiatrica Scandinavica, 2019-01, Vol.139 (1), p.68-77</ispartof><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2019 John Wiley & Sons A/S, Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4197-ad6ffe0438bed6c1b7e3db01f476618af332f42014ff6dc6277d90e1a333cfff3</citedby><cites>FETCH-LOGICAL-c4197-ad6ffe0438bed6c1b7e3db01f476618af332f42014ff6dc6277d90e1a333cfff3</cites><orcidid>0000-0001-9377-9436</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Facps.12957$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Facps.12957$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30182363$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kessing, L.V.</creatorcontrib><creatorcontrib>Rytgaard, H. C.</creatorcontrib><creatorcontrib>Gerds, T. A.</creatorcontrib><creatorcontrib>Berk, M.</creatorcontrib><creatorcontrib>Ekstrøm, C. T.</creatorcontrib><creatorcontrib>Andersen, P. K.</creatorcontrib><title>New drug candidates for depression – a nationwide population‐based study</title><title>Acta psychiatrica Scandinavica</title><addtitle>Acta Psychiatr Scand</addtitle><description>Objective
To investigate whether continued use of non‐aspirin NSAID, low‐dose aspirin, high‐dose aspirin, statins, allopurinol and angiotensin agents decreases the rate of incident depression using Danish nationwide population‐based registers.
Methods
All persons in Denmark who purchased the exposure medications of interest between 1995 and 2015 and a random sample of 30% of the Danish population was included in the study. Two different outcome measures were included, (i) a diagnosis of depressive disorder at a psychiatric hospital as in‐patient or out‐patient and (ii) a combined measure of a diagnosis of depression or use of antidepressants.
Results
A total of 1 576 253 subjects were exposed to one of the six drugs of interest during the exposure period from 2005 to 2015. Continued use of low‐dose aspirin, statins, allopurinol and angiotensin agents was associated with a decreased rate of incident depression according to both outcome measures. Continued uses of non‐aspirin NSAIDs as well as high‐dose aspirin were associated with an increased rate of incident depression.
Conclusion
The findings support the potential of agents acting on inflammation and the stress response system in depression as well as the potential of population‐based registers to systematically identify drugs with repurposing potential.</description><subject>Adult</subject><subject>Aged</subject><subject>Allopurinol</subject><subject>Allopurinol - adverse effects</subject><subject>Allopurinol - therapeutic use</subject><subject>Angiotensin</subject><subject>Angiotensins - adverse effects</subject><subject>Angiotensins - therapeutic use</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Antidepressants</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Aspirin</subject><subject>Aspirin - adverse effects</subject><subject>Aspirin - therapeutic use</subject><subject>Denmark - epidemiology</subject><subject>Depression - diagnosis</subject><subject>Depression - drug therapy</subject><subject>Depression - epidemiology</subject><subject>depressive disorder</subject><subject>Depressive Disorder - diagnosis</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - epidemiology</subject><subject>Diagnosis</subject><subject>Drug development</subject><subject>Drug dosages</subject><subject>Drug Repositioning - methods</subject><subject>Drug Repositioning - statistics & numerical data</subject><subject>drug repurposing</subject><subject>Female</subject><subject>Gout Suppressants - adverse effects</subject><subject>Gout Suppressants - therapeutic use</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Incidence</subject><subject>inflammation</subject><subject>Inflammation - drug therapy</subject><subject>Male</subject><subject>Mental depression</subject><subject>Middle Aged</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>NSAID</subject><subject>Outcome Assessment, Health Care</subject><subject>Population</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Registries</subject><subject>Statins</subject><subject>stress</subject><subject>Stress, Physiological - drug effects</subject><issn>0001-690X</issn><issn>1600-0447</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1KxDAURoMoOv5sfAAJuBGhem_TSdqlDP7BoIIK7kLa3Eil09ZkyjC7eQTBN_RJ7DjqwoXZXD44HMJhbB_hBPt3aoo2nGCcDdUaG6AEiCBJ1DobAABGMoOnLbYdwks_hwjpJtsSgGkspBiw8Q3NuPXdMy9MbUtrphS4azy31HoKoWxq_rF454bXZtqPWWmJt03bVV_zY_GWm0CWh2ln57tsw5kq0N733WGPF-cPo6tofHt5PTobR0WCmYqMlc4RJCLNycoCc0XC5oAuUVJiapwQsUtiwMQ5aQsZK2UzIDRCiMI5J3bY0crb-ua1ozDVkzIUVFWmpqYLOoYsS1MZI_bo4R_0pel83f9OxzhUGSSoltTxiip8E4Inp1tfToyfawS9bKyXjfVX4x4--FZ2-YTsL_oTtQdwBczKiub_qPTZ6O5-Jf0E0ayIbQ</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Kessing, L.V.</creator><creator>Rytgaard, H. C.</creator><creator>Gerds, T. A.</creator><creator>Berk, M.</creator><creator>Ekstrøm, C. T.</creator><creator>Andersen, P. K.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9377-9436</orcidid></search><sort><creationdate>201901</creationdate><title>New drug candidates for depression – a nationwide population‐based study</title><author>Kessing, L.V. ; Rytgaard, H. C. ; Gerds, T. A. ; Berk, M. ; Ekstrøm, C. T. ; Andersen, P. K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4197-ad6ffe0438bed6c1b7e3db01f476618af332f42014ff6dc6277d90e1a333cfff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Allopurinol</topic><topic>Allopurinol - adverse effects</topic><topic>Allopurinol - therapeutic use</topic><topic>Angiotensin</topic><topic>Angiotensins - adverse effects</topic><topic>Angiotensins - therapeutic use</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - adverse effects</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Antidepressants</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Aspirin</topic><topic>Aspirin - adverse effects</topic><topic>Aspirin - therapeutic use</topic><topic>Denmark - epidemiology</topic><topic>Depression - diagnosis</topic><topic>Depression - drug therapy</topic><topic>Depression - epidemiology</topic><topic>depressive disorder</topic><topic>Depressive Disorder - diagnosis</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - epidemiology</topic><topic>Diagnosis</topic><topic>Drug development</topic><topic>Drug dosages</topic><topic>Drug Repositioning - methods</topic><topic>Drug Repositioning - statistics & numerical data</topic><topic>drug repurposing</topic><topic>Female</topic><topic>Gout Suppressants - adverse effects</topic><topic>Gout Suppressants - therapeutic use</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Incidence</topic><topic>inflammation</topic><topic>Inflammation - drug therapy</topic><topic>Male</topic><topic>Mental depression</topic><topic>Middle Aged</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>NSAID</topic><topic>Outcome Assessment, Health Care</topic><topic>Population</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Registries</topic><topic>Statins</topic><topic>stress</topic><topic>Stress, Physiological - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kessing, L.V.</creatorcontrib><creatorcontrib>Rytgaard, H. C.</creatorcontrib><creatorcontrib>Gerds, T. A.</creatorcontrib><creatorcontrib>Berk, M.</creatorcontrib><creatorcontrib>Ekstrøm, C. T.</creatorcontrib><creatorcontrib>Andersen, P. K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Acta psychiatrica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kessing, L.V.</au><au>Rytgaard, H. C.</au><au>Gerds, T. A.</au><au>Berk, M.</au><au>Ekstrøm, C. T.</au><au>Andersen, P. K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New drug candidates for depression – a nationwide population‐based study</atitle><jtitle>Acta psychiatrica Scandinavica</jtitle><addtitle>Acta Psychiatr Scand</addtitle><date>2019-01</date><risdate>2019</risdate><volume>139</volume><issue>1</issue><spage>68</spage><epage>77</epage><pages>68-77</pages><issn>0001-690X</issn><eissn>1600-0447</eissn><abstract>Objective
To investigate whether continued use of non‐aspirin NSAID, low‐dose aspirin, high‐dose aspirin, statins, allopurinol and angiotensin agents decreases the rate of incident depression using Danish nationwide population‐based registers.
Methods
All persons in Denmark who purchased the exposure medications of interest between 1995 and 2015 and a random sample of 30% of the Danish population was included in the study. Two different outcome measures were included, (i) a diagnosis of depressive disorder at a psychiatric hospital as in‐patient or out‐patient and (ii) a combined measure of a diagnosis of depression or use of antidepressants.
Results
A total of 1 576 253 subjects were exposed to one of the six drugs of interest during the exposure period from 2005 to 2015. Continued use of low‐dose aspirin, statins, allopurinol and angiotensin agents was associated with a decreased rate of incident depression according to both outcome measures. Continued uses of non‐aspirin NSAIDs as well as high‐dose aspirin were associated with an increased rate of incident depression.
Conclusion
The findings support the potential of agents acting on inflammation and the stress response system in depression as well as the potential of population‐based registers to systematically identify drugs with repurposing potential.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>30182363</pmid><doi>10.1111/acps.12957</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-9377-9436</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-690X |
| ispartof | Acta psychiatrica Scandinavica, 2019-01, Vol.139 (1), p.68-77 |
| issn | 0001-690X 1600-0447 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2099886211 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Allopurinol Allopurinol - adverse effects Allopurinol - therapeutic use Angiotensin Angiotensins - adverse effects Angiotensins - therapeutic use Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antidepressants Antidepressive Agents - therapeutic use Aspirin Aspirin - adverse effects Aspirin - therapeutic use Denmark - epidemiology Depression - diagnosis Depression - drug therapy Depression - epidemiology depressive disorder Depressive Disorder - diagnosis Depressive Disorder - drug therapy Depressive Disorder - epidemiology Diagnosis Drug development Drug dosages Drug Repositioning - methods Drug Repositioning - statistics & numerical data drug repurposing Female Gout Suppressants - adverse effects Gout Suppressants - therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Incidence inflammation Inflammation - drug therapy Male Mental depression Middle Aged Nonsteroidal anti-inflammatory drugs NSAID Outcome Assessment, Health Care Population Population studies Population-based studies Registries Statins stress Stress, Physiological - drug effects |
| title | New drug candidates for depression – a nationwide population‐based study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T03%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20drug%20candidates%20for%20depression%20%E2%80%93%20a%20nationwide%20population%E2%80%90based%20study&rft.jtitle=Acta%20psychiatrica%20Scandinavica&rft.au=Kessing,%20L.V.&rft.date=2019-01&rft.volume=139&rft.issue=1&rft.spage=68&rft.epage=77&rft.pages=68-77&rft.issn=0001-690X&rft.eissn=1600-0447&rft_id=info:doi/10.1111/acps.12957&rft_dat=%3Cproquest_cross%3E2099886211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157904171&rft_id=info:pmid/30182363&rfr_iscdi=true |